Intervention/Treatment: The study tests the drug Dupilumab, administered subcutaneously, alongside a non-sedative antihistamine and a moisturizer. Dupilumab is designed to reduce inflammation and ...

Sanofi is currently conducting a Phase 3 clinical trial to evaluate the safety and effectiveness of a new 21-valent pneumococcal conjugate vaccine (PCV21) in healthy infants and toddlers. The study, ...

Sanofi (ENXTPA:SAN) has made a move that is bound to get investors talking, as shares edged up just over 5% in the past week. While there is no headline-making event at play, this uptick arrives after ...

A federal appeals court revived a lawsuit accusing Sanofi, Eli Lilly, Novo Nordisk, and AstraZeneca of conspiring to restrict ...

Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why SNY stock is a strong buy.

Novavax, Inc. (NASDAQ:NVAX) is a biotechnology company focused on recombinant protein-based vaccines using nanoparticle and ...

Sanofi's Tzield is now the first and only disease-modifying therapy to be approved for type 1 diabetes (T1D) in the UK.

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines ...

Sanofi SAN 0.11% is buying U.K. biotechnology company Vicebio for up to $1.6 billion in a deal that seeks to strengthen the French drugmaker’s portfolio of respiratory vaccines and help it move ...

Sanofi SAN -0.34% nudged up its full-year sales expectations after its top line grew faster than analysts expected for the second quarter due to drug launches and continued demand for its ...

Sanofi agreed to buy UK biotech Vicebio Ltd. for as much as $1.6 billion, gaining experimental vaccines and a technology to streamline their development. The acquisition helps Sanofi get closer to ...